Pro-Lab Diagnostics USA is a pioneering company in the healthcare industry, established in 1986 and headquartered in the United States. The company's mission is to deliver high-quality, cost-effective molecular and immunodiagnostic products, meeting rigorous standards set by governmental and international excellence organizations, such as ISO 13485:2003. Pro-Lab Diagnostics has made significant contributions to the U.S. Health and Safety market, particularly through innovative product introductions like the TransVelope™ specimen transport bag and the AmnioTest™ Nitrazine Swab, revolutionizing Point-of-Care testing in OB-GYN and birthing clinics. The company has also expanded its product line to include OptiGene products for molecular diagnostics. The company has a rich history of accomplishments since 1986 and has successfully widened its product offerings to include a superior line of latex agglutination products, comprehensive organism storage and retrieval systems, and a variety of general microbiology products. Pro-Lab Diagnostics prides itself on being a forward-thinking organization with a strong focus on making a positive impact on healthcare and individuals' lives. As a privately held corporation with its main office in Toronto, Canada, and subsidiaries in the U.K. and U.S.A., Pro-Lab Diagnostics stands as a testament to innovation and excellence in the healthcare and E-commerce industries. With a strong foundation and a track record of pioneering products, the company presents promising opportunities for potential venture capital investment.
There is no investment information
No recent news or press coverage available for Pro-Lab Diagnostics USA.